Nuvectis Pharma, Inc. NVCT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Nuvectis Pharma, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s return on equity?
- Nuvectis Pharma, Inc. (NVCT) reported return on equity of -154.4% in Q1 2026.
- How has Nuvectis Pharma, Inc.'s return on equity changed year-over-year?
- Nuvectis Pharma, Inc.'s return on equity decreased by 34.0% year-over-year, from -115.3% to -154.4%.
- What is the long-term trend for Nuvectis Pharma, Inc.'s return on equity?
- Over 2 years (2023 to 2025), Nuvectis Pharma, Inc.'s return on equity has grown at a 5.6% compound annual growth rate (CAGR), from -168.5% to -188%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.